- Top UN court to open unprecedented climate hearings
- European countries that allow assisted dying
- British MPs to debate contentious assisted dying law
- Schmidt not expecting hero's welcome on Ireland return
- PSG stuck between domestic dominance and Champions League woes
- 'Hot fight' as unbeaten Bayern visit Dortmund fortress
- Bordeaux-Begles' Samu 'not finished yet' with Wallabies
- Brook and Pope half-centuries haul England to 174-4 against NZ
- Yen rallies on rate hike bets as equity markets swing
- Ukraine superstar Mahuchikh brings 'good vibes' to her war-torn country
- PlayStation at 30: How Sony's grey box conquered gaming
- Saudi Arabia hosts UN talks on drought, desertification
- PlayStation: Fun facts to know as Sony's console turns 30
- Nepal's first transgender candidates run for local office
- Father of PlayStation says 'everyone told us we would fail'
- Ireland seek to overcome former coach Schmidt's Wallabies
- Detroit survive Bears comeback to make it 10 wins in a row
- Mexican actor Silvia Pinal dead at 93
- 'Black Friday' deals target inflation-weary US consumers
- Liverpool look to deepen Man City crisis, Amorim seeks first Premier League win
- Police fire rubber bullets, tear gas at Georgia protesters after PM delays EU bid
- England lose three quick wickets in reply to New Zealand's 348
- Social media companies slam Australia's under-16 ban
- Police fire tear gas at Georgia protesters after PM delays EU bid
- Canada watchdog sues Google over 'anti-competitive' ad tech
- Hojlund gives Amorim winning Old Trafford bow, Roma hold Spurs
- Amorim wins first Man Utd home game after rollercoaster ride
- France arrests 26 as South Asian migrant trafficking ring smashed
- At least 15 dead, 113 missing, in Uganda landslides
- Netanyahu threatens 'intensive war' if Hezbollah breaches fragile truce
- Bilbao join Lazio at Europa League summit, Chelsea cruise in Conference League
- In Lebanon's Tyre returning residents find no water, little power
- Protests in Georgia after PM delays EU bid to 2028
- Biden slams Trump tariff threats as 'counterproductive'
- TikTok tactics shake up politics in Romania
- 'He should do comedy' says Norris of Verstappen comments
- Americans celebrate Thanksgiving after bitter election
- Flood-hit Spain introduces 'climate leave' for workers
- UK's Starmer vows to slash net migration
- Recount order, TikTok claims throw Romania election into chaos
- Jansen stars for South Africa as Sri Lanka crumble to 42 all out
- Bottas set for Mercedes return as Mick Schumacher quits reserve role
- Putin threatens Kyiv with new hypersonic missile
- Georgia delays EU bid until 2028 amid post-election crisis
- French PM announces concession in bid to end budget standoff
- Guardiola's ingenuity will solve Man City crisis, says Slot
- South Africa in control after Sri Lanka crash to 42 all out
- 'Nothing left': Flood-hit Spanish town struggles one month on
- Israel conducts first strike on Lebanon since ceasefire
- 'Unrecognisable' Mbappe and Real Madrid hurting after European woes
Moderna sues Pfizer, BioNTech over Covid vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.
Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.
"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."
Pfizer pledged to "vigorously defend against the allegations of the lawsuit."
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.
The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.
O.Lorenz--BTB